Citigroup Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target lifted by Citigroup from $25.00 to $27.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “sell” rating on the stock. Citigroup’s target price indicates a potential downside of 47.44% from the company’s current price.

Several other brokerages also recently commented on HIMS. Needham & Company LLC increased their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler increased their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $30.67.

Hims & Hers Health Price Performance

HIMS opened at $51.37 on Tuesday. The firm has a market cap of $11.22 billion, a PE ratio of 116.75 and a beta of 1.35. The stock has a 50-day moving average price of $35.45 and a 200-day moving average price of $26.08. Hims & Hers Health has a 1 year low of $9.67 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at approximately $5,692,221.49. The trade was a 56.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,080,275 shares of company stock valued at $37,247,354 over the last ninety days. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. SlateStone Wealth LLC grew its holdings in shares of Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after acquiring an additional 628 shares during the last quarter. Quest Partners LLC increased its stake in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the period. Finally, Harbour Investments Inc. increased its position in shares of Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.